Innate and adaptive immune responses against coronavirus

Biomed Pharmacother. 2020 Dec:132:110859. doi: 10.1016/j.biopha.2020.110859. Epub 2020 Oct 22.

Abstract

Coronaviruses (CoVs) are a member of the Coronaviridae family with positive-sense single- stranded RNA. In recent years, the CoVs have become a global problem to public health. The immune responses (innate and adaptive immunity) are essential for elimination and clearance of CoVs infections, however, uncontrolled immune responses can result in aggravating acute lung injury and significant immunopathology. Gaining profound understanding about the interaction between CoVs and the innate and adaptive immune systems could be a critical step in the field of treatment. In this review, we present an update on the host innate and adaptive immune responses against SARS-CoV, MERS-CoV and newly appeared SARS-CoV-2.

Keywords: Adaptive immune response; COVID-19; Convalescent plasma therapy; Innate immune response; Monoclonal antibody therapy.

Publication types

  • Review

MeSH terms

  • Adaptive Immunity / drug effects
  • Adaptive Immunity / immunology*
  • Animals
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • COVID-19 / immunology*
  • COVID-19 / therapy
  • COVID-19 Serotherapy
  • Humans
  • Immunity, Innate / drug effects
  • Immunity, Innate / immunology*
  • Immunization, Passive
  • SARS-CoV-2 / drug effects
  • SARS-CoV-2 / immunology*
  • Virus Replication / drug effects
  • Virus Replication / immunology

Substances

  • Antibodies, Monoclonal